Patient Resources (English)

Use the downloads below to help your patients and families living with CGD. The information covers everything from tips on staying on treatment to explaining CGD in patient-friendly terms.

Image of CGD Facts PDF

CGD Facts

Lists easy-to-understand information about CGD to help patients, friends, family, and school staff learn more about the disease.

View Resource Email a Copy

Image of Family Testing Guide

Family Testing Guide

A guide to explain risks of CGD to family members and the importance of testing.

View Resource Email a Copy

Image of ACTIMMUNE® (Interferon gamma-1b) Injection Training Guide

Injection Training Guide

Provides injection reminders and shows patients how to measure the dose, choose the injection site, and store ACTIMMUNE.

View Resource Email a Copy

Image of Managing ACTIMMUNE® (Interferon gamma-1b) Side Effects

Managing Side Effects

Provides tips for patients to minimize common side effects, including advice on reducing symptoms like fever and headache.

View Resource Email a Copy

Patient Resources (Spanish)

Give your Spanish-speaking patients and their families the tools they need to help get started and stay on ACTIMMUNE treatment for chronic granulomatous disease (CGD).

Image of Chronic Granulomatous Disease Brochure in Spanish

Chronic Granulomatous Disease Brochure (Spanish)

Learn more about chronic granulomatous disease, including signs, symptoms, medications that help treat it, and more.

View Resource Email a Copy

Image of Injection Training Guide in Spanish

Injection Training Guide (Spanish)

Provides injection reminders and shows patients how to measure the dose, choose the injection site, and store ACTIMMUNE.

View Resource Email a Copy

Image of Managing Side Effects in Spanish

Managing Side Effects (Spanish)

Provides tips for patients to minimize common side effects, including advice on reducing symptoms like fever and headache.

View Resource Email a Copy

Image of CGD TRAQ brochure in Spanish

CGD TRAQ Brochure (Spanish)

An easy-to-use process and practical advice for teens who are ready to transition to self-care.

View Resource Email a Copy

Please note that these emails will be sent in Spanish and should be shared with a Spanish-speaking patient when possible.

Dedicated one-on-one support

Clinical Nurse Educators (CNEs), like Shannon, provide patients with non-medical, logistical support that helps them understand what to expect during treatment.

VIEW PDF

Download the Patient
Enrollment Form

To learn more, call 1 (844) 469-4297 or visit https://www.horizonbyyourside.com/ACTIMMUNE/hcp

Horizon By Your Side is a patient support program for patients prescribed ACTIMMUNE.

The dedicated members of the Horizon By Your Side team provide personalized service to CGD patients so they can have support and injection training with ACTIMMUNE.

Clinical Nurse Educators (CNEs) work directly with individual patients to answer non-medical, logistical questions and provide support upon enrollment. Additionally, the CNE educates about navigating insurance processes and accessing treatment on your patient’s behalf. The CNE has the expertise and tools to support the patient by educating on patient benefits, prior authorization requirements, payor policies, and coding and claim submissions.

These services are offered to ACTIMMUNE patients upon enrollment with the Patient Enrollment Form (PEF) and completed patient consent. The services are built around 3 components: connect, coordinate, and champion.

The Horizon By Your Side team helps

Connect icon

CONNECT: Your patient will be paired with a Clinical Nurse Educator who can provide tools and resources to help your patient manage their day-to-day challenges.

Coordinate icon

COORDINATE: The Horizon By Your Side team can help patients address financial barriers by researching their insurance benefits, explaining insurance options, and connecting them to financial assistance if eligible.

Champion icon

CHAMPION: The Clinical Nurse Educator will serve as a dedicated personal resource and main point of contact for your patient’s ongoing non-medical needs.

Download the patient
enrollment form
Learn more about navigating
the payor access journey

Approved Uses and Important Safety Information

INDICATIONS AND USAGE

ACTIMMUNE® (Interferon gamma-1b) is indicated:

  • For reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease
  • For delaying time to disease progression in patients with severe, malignant osteopetrosis
IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • In patients who develop or have known hypersensitivity to interferon-gamma, E. coli derived products, or any component of the product

WARNINGS AND PRECAUTIONS

  • ACTIMMUNE should be used with caution in patients with:
    • Pre-existing cardiac conditions, including ischemia, congestive heart failure, or arrhythmia
    • Seizure disorders or compromised central nervous system function; reduce dose or discontinue
    • Myelosuppression, or receiving other potentially myelosuppressive agents; consider dose reduction or discontinuation of therapy
    • Severe renal insufficiency
    • Age <1 year
  • Monitoring:
    • Patients begun on ACTIMMUNE before age 1 year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified
    • Monitor renal function regularly when administering ACTIMMUNE in patients with severe renal insufficiency; accumulation of interferon gamma-1b may occur with repeated administration. Renal toxicity has been reported in patients receiving ACTIMMUNE
  • Pregnancy, Lactation, and Fertility:
    • ACTIMMUNE should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus
    • Use of ACTIMMUNE by lactating mothers is not recommended. ACTIMMUNE or nursing should be discontinued dependent on the importance of the drug to the mother
    • Long-term effects of ACTIMMUNE on fertility are not known

DRUG INTERACTIONS

  • Concomitant use of drugs with neurotoxic, hematotoxic, or cardiotoxic effects may increase the toxicity of interferons
  • Avoid simultaneous administration of ACTIMMUNE with other heterologous serum protein or immunological preparations (eg, vaccines)

ADVERSE REACTIONS

  • The most common adverse experiences occurring with ACTIMMUNE therapy are “flu-like” symptoms such as fever, headache, chills, myalgia, or fatigue, which may decrease in severity as treatment continues, and may be minimized by bedtime administration of ACTIMMUNE. Acetaminophen may be used to prevent or partially alleviate the fever and headache
  • Isolated cases of acute serious hypersensitivity reactions have been observed in patients receiving ACTIMMUNE
  • Reversible neutropenia, thrombocytopenia, and elevations of AST and/or ALT have been observed during ACTIMMUNE therapy
  • At doses 10 times greater than the weekly recommended dose, ACTIMMUNE may exacerbate pre-existing cardiac conditions, or may cause reversible neurological effects such as decreased mental status, gait disturbance, and dizziness

Approved Uses and Important Safety Information

INDICATIONS AND USAGE

ACTIMMUNE® (Interferon gamma-1b) is indicated:

  • For reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease
  • For delaying time to disease progression in patients with severe, malignant osteopetrosis
IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • In patients who develop or have known hypersensitivity to interferon-gamma, E. coli derived products, or any component of the product

WARNINGS AND PRECAUTIONS

  • ACTIMMUNE should be used with caution in patients with:
    • Pre-existing cardiac conditions, including ischemia, congestive heart failure, or arrhythmia
    • Seizure disorders or compromised central nervous system function; reduce dose or discontinue
    • Myelosuppression, or receiving other potentially myelosuppressive agents; consider dose reduction or discontinuation of therapy
    • Severe renal insufficiency
    • Age <1 year
  • Monitoring:
    • Patients begun on ACTIMMUNE before age 1 year should receive monthly assessments of liver function. If severe hepatic enzyme elevations develop, ACTIMMUNE dosage should be modified
    • Monitor renal function regularly when administering ACTIMMUNE in patients with severe renal insufficiency; accumulation of interferon gamma-1b may occur with repeated administration. Renal toxicity has been reported in patients receiving ACTIMMUNE
  • Pregnancy, Lactation, and Fertility:
    • ACTIMMUNE should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus
    • Use of ACTIMMUNE by lactating mothers is not recommended. ACTIMMUNE or nursing should be discontinued dependent on the importance of the drug to the mother
    • Long-term effects of ACTIMMUNE on fertility are not known

DRUG INTERACTIONS

  • Concomitant use of drugs with neurotoxic, hematotoxic, or cardiotoxic effects may increase the toxicity of interferons
  • Avoid simultaneous administration of ACTIMMUNE with other heterologous serum protein or immunological preparations (eg, vaccines)

ADVERSE REACTIONS

  • The most common adverse experiences occurring with ACTIMMUNE therapy are “flu-like” symptoms such as fever, headache, chills, myalgia, or fatigue, which may decrease in severity as treatment continues, and may be minimized by bedtime administration of ACTIMMUNE. Acetaminophen may be used to prevent or partially alleviate the fever and headache
  • Isolated cases of acute serious hypersensitivity reactions have been observed in patients receiving ACTIMMUNE
  • Reversible neutropenia, thrombocytopenia, and elevations of AST and/or ALT have been observed during ACTIMMUNE therapy
  • At doses 10 times greater than the weekly recommended dose, ACTIMMUNE may exacerbate pre-existing cardiac conditions, or may cause reversible neurological effects such as decreased mental status, gait disturbance, and dizziness